| scholarly article | Q13442814 |
| P50 | author | Sophie A Millar | Q60327555 |
| P2093 | author name string | Saoirse E O'Sullivan | |
| Andrew S Yates | |||
| Nicole L Stone | |||
| P2860 | cites work | Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia | Q24607361 |
| A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. | Q51348488 | ||
| A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray. | Q51350478 | ||
| High-Dose Cannabidiol Induced Hypotension after Global Hypoxia-Ischemia in Piglets. | Q52093087 | ||
| Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. | Q52655447 | ||
| Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. | Q53835626 | ||
| Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsiv | Q56768080 | ||
| Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome | Q62868130 | ||
| Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome | Q62868237 | ||
| Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects | Q83630498 | ||
| Involvement of UDP-glucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse | Q85643808 | ||
| Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis | Q87347315 | ||
| Human cannabinoid pharmacokinetics | Q24652736 | ||
| Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860606 | ||
| Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review | Q28300877 | ||
| Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice | Q30468504 | ||
| A new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis | Q30670447 | ||
| How important are sex differences in cannabinoid action? | Q34098223 | ||
| Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report | Q34137084 | ||
| Cannabidiol: an overview of some pharmacological aspects | Q34157378 | ||
| Cannabinoid disposition in oral fluid after controlled cannabis smoking in frequent and occasional smokers. | Q34216957 | ||
| Safety and side effects of cannabidiol, a Cannabis sativa constituent | Q34634008 | ||
| Reintoxication: the release of fat-stored delta(9)-tetrahydrocannabinol (THC) into blood is enhanced by food deprivation or ACTH exposure | Q34997474 | ||
| Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb | Q35001117 | ||
| Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans | Q35665889 | ||
| Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis | Q37006281 | ||
| Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration | Q37029480 | ||
| Plasma Cannabinoid Pharmacokinetics following Controlled Oral Δ9-Tetrahydrocannabinol and Oromucosal Cannabis Extract Administration | Q37029488 | ||
| Cannabinoid disposition in oral fluid after controlled smoked cannabis | Q37029531 | ||
| Effect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects | Q37263381 | ||
| Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults | Q37378093 | ||
| Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis | Q39181416 | ||
| Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration | Q39372201 | ||
| A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray | Q39816175 | ||
| Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines | Q41003488 | ||
| A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers | Q41453985 | ||
| Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. | Q44682452 | ||
| Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration | Q44941523 | ||
| Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans | Q45292449 | ||
| Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract | Q46819181 | ||
| Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract | Q46852361 | ||
| Sample size calculations based on generalized estimating equations for population pharmacokinetic experiments | Q47343314 | ||
| The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model | Q47960172 | ||
| Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial | Q48065074 | ||
| Interactions between cannabidiol and commonly used antiepileptic drugs. | Q48283873 | ||
| Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology | Q48325031 | ||
| Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn's Disease, a Randomized Controlled Trial. | Q48353765 | ||
| PTL401, a New Formulation Based on Pro-nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers | Q49487194 | ||
| Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial | Q50109024 | ||
| Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration | Q50176522 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| cannabidiol | Q422917 | ||
| cannabinoids | Q422936 | ||
| systematic review | Q1504425 | ||
| P304 | page(s) | 1365 | |
| P577 | publication date | 2018-11-26 | |
| P1433 | published in | Frontiers in Pharmacology | Q2681208 |
| P1476 | title | A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans | |
| P478 | volume | 9 |
| Q92701738 | A Novel Self-Emulsifying Drug Delivery System (SEDDS) Based on VESIsorb® Formulation Technology Improving the Oral Bioavailability of Cannabidiol in Healthy Subjects |
| Q67223781 | A systematic review of cannabidiol dosing in clinical populations |
| Q90598976 | As CBD skyrockets in popularity, scientists scramble to understand how it's metabolized |
| Q92647729 | Cannabidiol (CBD) for Treatment of Neurofibromatosis-related Pain and Concomitant Mood Disorder: A Case Report |
| Q90020725 | Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice |
| Q98282015 | Cannabidivarin for HIV-associated neuropathic pain - a randomized, blinded, controlled clinical trial |
| Q90225336 | Dual-Purpose Materials Based on Carbon Xerogel Microspheres (CXMs) for Delayed Release of Cannabidiol (CBD) and Subsequent Aflatoxin Removal |
| Q99711797 | Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products |
| Q89579808 | Neuroprotection Following Concussion: The Potential Role for Cannabidiol |
| Q98164603 | Plasma concentrations of eleven cannabinoids in cattle following oral administration of industrial hemp (Cannabis sativa) |
| Q89967869 | Preliminary Investigation of the Safety of Escalating Cannabinoid Doses in Healthy Dogs |
| Q98507441 | The Essential Medicinal Chemistry of Cannabidiol (CBD) |
| Q100395314 | The electrophysiological effect of cannabidiol on hERG current and in guinea-pig and rabbit cardiac preparations |
| Q92878674 | The nephrologist's guide to cannabis and cannabinoids |
Search more.